BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11805203)

  • 1. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)- 4-oxobut-2-enoate-sodium (PD 155080).
    Brunner F; Wölkart G; Haleen S
    J Pharmacol Exp Ther; 2002 Feb; 300(2):442-9. PubMed ID: 11805203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of endothelin antagonism on contractility, intracellular calcium regulation and calcium regulatory protein expression in right ventricular hypertrophy of the rat.
    Stessel H; Brunner F
    Basic Clin Pharmacol Toxicol; 2004 Jan; 94(1):37-45. PubMed ID: 14725613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium handling and role of endothelin-1 in monocrotaline right ventricular hypertrophy of the rat.
    Wölkart G; Strömer H; Brunner F
    J Mol Cell Cardiol; 2000 Nov; 32(11):1995-2005. PubMed ID: 11040104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
    Hill NS; Warburton RR; Pietras L; Klinger JR
    J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats.
    Prié S; Leung TK; Cernacek P; Ryan JW; Dupuis J
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1312-8. PubMed ID: 9316840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac endothelin and big endothelin in right-heart hypertrophy due to monocrotaline-induced pulmonary hypertension in rat.
    Brunner F
    Cardiovasc Res; 1999 Oct; 44(1):197-206. PubMed ID: 10615403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.
    Miyauchi T; Yorikane R; Sakai S; Sakurai T; Okada M; Nishikibe M; Yano M; Yamaguchi I; Sugishita Y; Goto K
    Circ Res; 1993 Nov; 73(5):887-97. PubMed ID: 8403258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade.
    Jasmin JF; Cernacek P; Dupuis J
    Clin Sci (Lond); 2003 Dec; 105(6):647-53. PubMed ID: 12823096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceleration of Ca2+ waves in monocrotaline-induced right ventricular hypertrophy in the rat.
    Miura M; Hirose M; Endoh H; Wakayama Y; Sugai Y; Nakano M; Fukuda K; Shindoh C; Shirato K; Shimokawa H
    Circ J; 2011; 75(6):1343-9. PubMed ID: 21467666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb.
    Coe Y; Haleen SJ; Welch KM; Liu YA; Coceani F
    J Pharmacol Exp Ther; 2002 Aug; 302(2):672-80. PubMed ID: 12130731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.
    Nishida M; Eshiro K; Okada Y; Takaoka M; Matsumura Y
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):187-91. PubMed ID: 15243299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
    Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium mishandling impairs contraction in right ventricular hypertrophy prior to overt heart failure.
    Power AS; Hickey AJ; Crossman DJ; Loiselle DS; Ward ML
    Pflugers Arch; 2018 Jul; 470(7):1115-1126. PubMed ID: 29525825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
    Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
    Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
    Kosanovic D; Kojonazarov B; Luitel H; Dahal BK; Sydykov A; Cornitescu T; Janssen W; Brandes RP; Davie N; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Schermuly RT
    Respir Res; 2011 Jun; 12():87. PubMed ID: 21699729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective effect of cerium oxide nanoparticles in monocrotaline rat model of pulmonary hypertension: A possible implication of endothelin-1.
    Nassar SZ; Hassaan PS; Abdelmonsif DA; ElAchy SN
    Life Sci; 2018 May; 201():89-101. PubMed ID: 29588134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
    Jasmin JF; Mercier I; Dupuis J; Tanowitz HB; Lisanti MP
    Circulation; 2006 Aug; 114(9):912-20. PubMed ID: 16940204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.